About Us
Delivering innovative solutions to guarantee the genetic quality of future therapies
Cergentis, a Solvias company, is a genomics-focused biotechnology company and leading provider of genetic quality control solutions, based on its proprietary Targeted Locus Amplification (TLA) technology platform.
With our widely published and recognized genetic analyses, we support all leading pharma companies and research institutes in the characterization and QC of their genetically engineered (animal) models, biopharmaceutical cell line development, and cell and gene therapy products.
By helping to de-risk R&D program decisions, minimizing time-to-clinic, providing objective genomic evidence to regulators, and supporting patient safety, we aim to support biopharmaceutical medicine programs worldwide.
Cergentis was founded in 2012 as a spin-off from Hubrecht Institute for Development Biology & Stem Cell Research and Royal Netherlands Academy of Arts and Sciences (KNAW).
In July 2022, Cergentis became part of Solvias. Read the press release here.